The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity

Targetting the ubiquitin pathway is an attractive strategy for cancer therapy. The inhibitor of the ubiquitin-like molecule NEDD8 pathway, MLN4924 (Pevonedistat) is in Phase II clinical trials. Protection of healthy cells from the induced toxicity of the treatment while preserving anticancer efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Malhab, Lara J. Bou, Descamps, Simon, Delaval, Benedicte, Xirodimas, Dimitris P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129021/
https://www.ncbi.nlm.nih.gov/pubmed/27901050
http://dx.doi.org/10.1038/srep37775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129021/
https://www.ncbi.nlm.nih.gov/pubmed/27901050
http://dx.doi.org/10.1038/srep37775

Ejemplares similares